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Abstract
Aims Synchronized diaphragmatic stimulation (SDS) modulates intrathoracic and intra-abdominal pressures with favourable
effects on cardiac function for patients with a reduced left ventricular ejection fraction (LVEF) and heart failure (HFrEF).
VisONE-HF is a ﬁrst-in-patient, observational study assessing the feasibility and 1 year effects of a novel, minimally invasive
SDS device.
Methods and results The SDS system comprises a pulse generator and two laparoscopically delivered, bipolar,
active-ﬁxation leads on the inferior diaphragmatic surface. Fifteen symptomatic men with HFrEF and ischaemic heart disease
receiving guideline-recommended therapy were enrolled (age 60 [56, 67] years, New York Heart Association class II [53%] /III
[47%], LVEF 27 [23, 33] %, QRSd 117 [100, 125] ms, & N terminal pro brain natriuretic peptide [NT-proBNP] 1779
[911, 2,072] pg/mL). Implant success was 100%. Patients were evaluated at 3, 6, and 12 months for device-related or
lead-related complications, quality of life (SF-36 QOL), 6 min hall walk distance (6MHWd), and by echocardiography. No
implant procedure or SDS-related adverse event occurred, and patients were unaware of diaphragmatic stimulation. By
12 months, left ventricular end-systolic volume decreased (136 [123, 170] mL to 98 [89, 106] mL; P = 0.05), 6MHWd increased (315 [300, 330] m to 340 [315, 368] m; P = 0.004), and SF-36 QOL improved (physical scale 0 [0, 0] to 25 [0,
50], P = 0.006; emotional scale 0 [0, 33] to 33 [33, 67], P = 0.001). Although neither reached statistical signiﬁcance, LVEF
decreased (28 [23, 40]% vs. 34 [29, 38]%; P = ns) and NT-proBNP was lower (1784 [920, 2540] pg/mL vs. 1492 [879,
2028] pg/mL; P = ns).
Conclusions These data demonstrate the feasibility of laparoscopic implantation and delivery of SDS without raising safety
concerns. These encouraging ﬁndings should be investigated further in adequately powered randomized trials.
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Introduction
Despite successes in pharmacological and device therapy for
patients with a reduced left ventricular ejection fraction
(LVEF) and heart failure (HFrEF), many patients remain symp-

tomatic, quality of life is often persistently poor; episodes of
decompensation are not uncommon; and for patients whose
congestion cannot be controlled, the prognosis is poor. For
patients with HFrEF in sinus rhythm and a prolonged QRS duration, cardiac resynchronization therapy (CRT) is often highly
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effective. For patients with HFrEF who are not candidates for
CRT, there is some evidence, although not robust, to support
cardiac contractility modulation devices1 and baroreﬂex activation therapy.2
Synchronized diaphragmatic stimulation (SDS) is a novel
concept designed to deliver cardiac-cycle-gaited reductions
in intrathoracic pressure by stimulating the diaphragm at
the appropriate time in the cardiac cycle, thereby increasing
systemic venous return but reducing atrial pressure.3 The
stimulus and diaphragmatic contraction are imperceptible
to the patient. A small, randomized cross-over trial that used
the atrial lead from a CRT device to deliver diaphragmatic
pacing synchronized to bi-ventricular pacing suggested that
3 weeks of diaphragmatic pacing could improve breathlessness, exercise capacity, and LVEF.4 Haemodynamic effects
may have been sustained for up to 1 year.5
Here, we present the results of the VisONE-HF ﬁrst-in-human study where patients with symptomatic HFrEF despite
guideline-recommended pharmacological therapy received
continuous SDS for 1 year using the laparoscopically implanted VisONE SDS system. This presents the ﬁrst study to
investigate the effect of chronic diaphragmatic stimulation
in heart failure.

A. Jorbenadze et al.

tomatic despite guideline-recommended therapy and who
were not indicated for CRT. The main safety outcome was
freedom from serious complications or adverse events at 3
and 12 months. The research protocol was approved by the
local ethics committee and complied with the Declaration
of Helsinki. All patients were required to provide written informed consent.
New York Heart Association (NYHA) functional class, quality of life (SF-36), 6 min hall walk distance, spirometry, plasma
concentrations of N terminal pro brain natriuretic peptide
(NT-proBNP), and LVEF and left ventricular end-systolic volume by echocardiography were assessed prior to discharge
with SDS programmed off, and at 3, 6, and 12 months, with
SDS programmed on (Figure 1).

Inclusion and exclusion criteria
Patients in NYHA class II/III on guideline-recommended treatment with an LVEF ≤ 35%, NT-proBNP > 500 pg/mL
(>250 pg/mL if on loop diuretics), in sinus rhythm with
<10% ventricular ectopy were included. The main exclusion
criteria were substantial pulmonary disease, contraindications to laparoscopy, QRS duration ≥140 ms or, within the
previous 3 months, an acute coronary syndrome, cardiac
procedure, or sustained ventricular arrhythmia.

Methods
Study design

Echocardiographic imaging

This ﬁrst-in-human study was a prospective, multicentre,
multinational, observational study investigating the feasibility
of delivering SDS to patients with HFrEF who remained symp-

Two-dimensional and Doppler echocardiography were done
in a recumbent left-lateral position by trained personnel following American Society of Echocardiography standards

Figure 1 Study design for the VisONE heart failure study.
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using a Philips iE33 system (Philips, Bothell, WA, USA). A
blinded analysis was performed by a core echocardiography
laboratory (University Heart Center, Zurich, Switzerland).
LVEF was calculated using the biplane Simpson’s method.

Synchronized diaphragmatic stimulation system
The SDS system consists of an implantable pulse generator
(IPG), two suture-less pacing/sensing leads and a tailored laparoscopic delivery tool to place the leads onto the inferior
surface of the diaphragm (Figure 2A). An external programmer is used to synchronize diaphragmatic pacing to the cardiac cycle with an adjustable delay. The IPG also records
accelerometer-based hourly activity.

Implantation procedure for synchronized
diaphragmatic stimulation
Using a sterile laparoscopic technique, the SDS leads were implanted via minimally invasive abdominal access (Figure 2B).
An initial 1 cm midline incision was made to place the trocar
and laparoscope; the abdomen was insufﬂated to allow adequate visualization of the diaphragm and surrounding organs.

Another small incision was made laterally to place another
trocar for lead insertion using a specialized tool to attach
the stimulating lead to the left diaphragm and the sensing
lead to the right. A subcutaneous pocket was created for
the IPG, and the leads tunnelled to connect to it. Sensing
and stimulating thresholds were then tested, and the diaphragmatic capture threshold was determined. To document
lead placement, a lateral chest X-ray was done (Figure 2C).
After the effects of general anaesthesia had resolved, the
acute effect of SDS on cardiac function was measured using
a thermodilution catheter (Edwards Lifesciences) and
echocardiography.
The SDS system senses the intrinsic QRS complex and then,
at a programmed delay, stimulates the left hemi-diaphragm.
This information is stored on the IPG. The SDS ‘dose–response’
(% SDS) is deﬁned by the percentage of QRS complexes
followed by diaphragmatic pacing.

Statistical analysis
Continuous variables are presented as the median with
[interquartile range]. Categorical variables are presented as
N (%). For comparisons of continuous variables, the t-test or

Figure 2 (A) Components of the implantable SDS therapy system; (B) anatomic locations used during laparoscopic implant of the SDS system: (1) trocar location for the laparoscope, (2) trocar location for insertion of sensing/stimulating leads, (3) diaphragmatic lead attachment locations, and (4)
subcutaneous pocket; (C) chest X-ray imaging of fully implanted IPG and leads; visualization of the inferior left hemisphere of the diaphragm with pacing lead attached, post-implant procedure with residual infra-diaphragmatic gas accumulation (expected).
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paired t-test was used as appropriate. A two-sided P
value < 0.05 was used to indicate statistical signiﬁcance.
Statistical analyses were performed using R, Version 3.4.1
(2017-06-30 for Windows) and Excel for Microsoft 365, Version 16.0 (Microsoft Corporation, Washington, USA).

Results
Baseline demographics
Nineteen patients were invited to participate in this study,
and 15 men agreed. Median age was 60 [56, 67] years,
53% were in NYHA Class II and the others in NYHA Class
III, LVEF was 27 [23, 33] %, QRS duration was 117 [100,
125] ms, and median plasma NT-proBNP was 1779 [911,
2072] pg/mL (Table 1). All patients were in sinus rhythm
and had ischaemic heart disease. Prescription of
guideline-recommended pharmacological therapy for heart
failure was high. There were very few adjustments to these
prescriptions during follow up: one patient had bisoprolol

2.5 mg/day discontinued at 6 months and another discontinued amlodipine 10 mg/day at 3 months.

Implant procedure and acute changes with
synchronized diaphragmatic stimulation
The average procedure time was 73 min. All patients
underwent SDS implantation with no device or
procedure-related adverse events. Average minimum stimulation energy to capture the diaphragm was 2.5 [1.75, 2.75]
V at pulse widths of 0.4 [0.4, 0.4] ms. For all patients, while
conscious, the diaphragmatic stimulation capture threshold
was identiﬁed by palpation of the abdomen. The energy (voltage or pulse-width) was increased until the patient became
aware of the stimulus. The IPG was then set to deliver a stimulus well below this threshold (6.0 [5.0, 7.5] V at pulse widths
of 0.4 [0.4, 0.4] ms). Temporary activation of SDS for approximately 5 min in conscious patients was associated with a
17% increase in cardiac output (SDS off: 4.8 [4.0, 5.4] vs.
SDS on: 5.7 [4.7, 5.9] L/min, Wilcoxon paired P < 0.001) with
little change in heart rate (SDS off: 81 [72, 88] vs. SDS on: 82

Table 1 Baseline characteristics of participating patients
Characteristic
Age (years)
Men
Medical history
Hypertension
T2DM
IHD
CABG
PTCA
CVA/TIA
Clinical characteristics
NYHA class
II
III
2
BMI (kg/m )
Heart rate (b.p.m.)
BP systolic (mmHg)
BP diastolic (mmHg)
SpO2 (%)
QRSd (ms)
Ejection fraction (%)
6MHW distance (m)
NT-proBNP (pg/mL)
Creatinine (μmol/L)
Sodium (mmol/L)
Potassium (mmol/L)
Haemoglobin (g/dL)
eGFR (mL/min)
FEV1 (L)
FVC (L)

All participants (n = 15)

% SDS ≥ 80% group (n = 9)

61, 60 [56, 67]
15 (100%)

64, 66 [58, 68]
9 (100%)

10 (66.7%)
5 (33.3%)
15 (100%)
6 (40.0%)
10 (66.7%)
1 (6.7%)

7 (77.8%)
3 (33.3%)
9 (100%)
4 (44.4%)
5 (55.6%)
1 (11.1%)

8 (53.3%)
7 (46.7%)
28, 28 [26, 31]
74, 71 [63, 87]
122, 120 [116, 131]
69, 68 [65, 78]
97, 98 [97, 98]
114, 117 [100, 125]
28, 27 [23, 33]
304, 308 [295, 323]
1579, 1779 [911, 2072]
122, 119 [105, 137]
139, 138 [137, 140]
4.6, 4.7 [4.1, 5.0]
139, 139 [127, 153]
71, 67 [56, 78]
2.6, 2.7 [2.5, 2.8]
3.2, 3.2 [3.1, 3.4]

7 (77.8%)
2 (22.2%)
28, 28 [26, 29]
70, 68 [60, 82]
122, 120 [118, 128]
71, 68 [67, 78]
97, 98 [97, 98]
115, 113 [104, 120]
29, 30 [26, 32]
305, 308 [302, 332]
1437, 1025 [965, 1901]
120, 119 [105, 137]
139, 139 [137, 140]
4.5, 4.2 [4.1, 4.9]
135, 132 [127, 149]
66, 67 [56, 77]
2.5, 2.7 [2.5, 2.8]
3.1, 3.2 [3.0, 3.4]

6MHW, 6 min hall walk; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass graft; CVA, cerebrovascular accident;
eGFR, estimated glomerular ﬁltration rate; FCV, forced vital capacity; FEV1, forced expiratory volume, ﬁrst recording; IHD, ischemic heart
disease; PTCA, percutaneous transluminal coronary angioplasty; QRSd, QRS duration; TIA, transient ischaemic attack; T2DM, type 2 diabetes mellitus.
Values are presented as mean, median, and [quartiles] or for categorical variables, n (%).
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[74, 88] b.p.m.). All patients were discharged with SDS turned
on at a stimulation output imperceptible to the patient.

and no patient complained of symptoms due to diaphragmatic stimulation.

Follow up

Laboratory data and spirometry results

Changes in lead impedance were monitored throughout the
study, revealing a reduction within a few hours after implantation and no signiﬁcant changes thereafter. Average lead impedance was 1608 [1434, 1874] Ω at implant, 528 [469, 605]
Ω at discharge, 493 [413, 581] Ω at 3 months, 503 [466, 573]
Ω at 6 months, and 451 [361, 493] Ω at 12 months. Capture
and symptomatic thresholds were determined at each follow
up. No signiﬁcant adjustments were necessary. Programmed
stimulation voltages were 2.5 [2.0, 4.5] V at discharge, 2.5
[1.75, 3.5] V at 3 months, 2.5 [1.75, 3.5] V at 6 months, and
2.5 [2.0, 3.5] V at 12 months. Interrogation of the IPG found
that nine patients had ≥80% SDS and six had <80% SDS (refer
to Supporting Information, Figures S1–S2).

Plasma concentrations of NT-proBNP were similar at baseline
and 1 year (Table 2), although there was a trend for lower
values when SDS was ≥80% (Table 3). Serum creatinine was
lower at 12 months when SDS was ≥80% (discharge 1.26
[1.21, 1.33] vs 12-months 1.17 [1.08, 1.29] mg/dL, P = 0.03).
There were no signiﬁcant changes in forced expiratory volumes or forced vital capacity.

Safety and adverse events
One patient was considered ineligible for the safety analysis
due to undisclosed, pre-enrolment, and ongoing pulmonary
effusions, which constituted a protocol violation. This patient, who had SDS <80%, died just prior to his 6 month follow up from heart failure. One patient, who had SDS <80%,
died 11 months into the study due to an infection while hospitalized for nephrolithotomy unrelated to SDS. During the
study, there was one serious adverse event (pneumothorax)
due to central line placement, one mild adverse event (superﬁcial wound infection), two moderate adverse events
(sprained ankle, decompensation of heart failure), and two
severe adverse events (cholelithiasis, acute decompensation
of heart failure). Other than the superﬁcial wound infection,
no adverse events related to the SDS procedure, device or
leads were reported during the 12 month study period,

Effect of synchronized diaphragmatic stimulation
on functional status, exercise capacity, and
quality of life
Six-minute hall walk (6MHW) distance increased from discharge to follow up at 12 months (discharge 315 [300, 330]
vs. 12 months 340 [315, 368] m, P = 0.004) with slightly
greater improvements when SDS was ≥80% (Figure 3 &
Table 3). QOL, as assessed by the SF-36 questionnaire, also
improved both for physical (discharge 0 [0, 0] vs. 6 months
38 [0, 50], P = 0.002; 12 months 25 [0, 50] au, P = 0.006)
and emotional aspects (discharge 0 [0, 33] vs. 6 months 50
[0, 67], P = 0.02; 12 months 33 [33, 67] au, P = 0.001). Again,
the effect was greater when SDS was ≥80%. Day-time activity
increased between 3 and 12 months, with both values being
higher, as expected, than activity recorded during the 3 days
after discharge (Table 3). During 12 months follow up, LV
end-systolic volume fell from 136 [123, 170] to 98 [89, 106]
mL (P = 0.05); the effect was not greater in patients with
SDS ≥80%. A trend to increasing LVEF in the overall cohort
(28 [23, 40] % to 34 [29, 38] %, P = ns) was signiﬁcant for
those with SDS ≥80% (28 [23, 40] % vs. 34 [34, 38] %,
P = 0.005).

Table 2 Change in laboratory and spirometry variables following SDS
Parameter

Discharge

NT-proBNP (pg/mL)
All (n = 15)
1669, 1784 [920, 2540]
% SDS ≥ 80% (n = 9)
1470, 1020 [968, 1898]
Creatinine (μmol/L)
All (n = 15)
115, 111 [107, 125]
% SDS ≥ 80% (n = 9)
115, 111 [107, 118]
Forced expiratory volume (FEV) (L)
All (n = 15)
2.6, 2.6 [2.5, 2.8]
% SDS ≥ 80% (n = 9)
2.4, 2.6 [2.5, 2.6]
Forced vital capacity (FVC) (L)
All (n = 15)
3.2, 3.1 [2.9, 3.5]
% SDS ≥ 80% (n = 9)
3.0, 3.1 [2.9, 3.2]

3 month follow up

6 month follow up

12 month follow up

1775, 1190 [871, 2059]
1215, 1024 [871, 1797]

1556, 1161 [910, 1708]
1110, 1020 [910, 1400]

1488, 1492 [879, 2028]
1218, 962 [736, 1673]

120, 115 [100, 131]
112, 115 [100, 118]

107, 104 [93, 127]
106, 98 [93, 117]

108, 106 [97, 120]
104, 103 [95, 114]*

2.6, 2.5 [2.4, 2.8]
2.5, 2.5 [2.5, 2.7]

2.6, 2.6 [2.5, 2.7]
2.5, 2.6 [2.5, 2.7]

2.5, 2.5 [2.3, 2.7]
2.4, 2.5 [2.2, 2.7]

3.2, 3.2 [3.0, 3.4]
3.1, 3.2 [3.0, 3.4]

3.1, 3.1 [3.0, 3.5]
3.1, 3.0 [3.0, 3.2]

3.0, 3.1 [2.9, 3.2]
2.9, 3.0 [2.9, 3.2]

Values are mean, median, and [quartiles]. One patient with SDS < 80% died before the 6 month assessment. One patient with SDS < 80%
died before the 12 month assessment.
*
P value < 0.05 follow up compared with discharge.
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Table 3 Change in exercise capacity, quality of life, physical activity, and echocardiography following SDS
Parameter

Discharge

6 min walk test distance (m)
All (n = 15)
305, 315 [300, 330]
% SDS ≥ 80% (n = 9)
293, 315 [292, 318]
SF-36 Role limitations, physical
All
7, 0 [0, 0]
% SDS ≥ 80%
3, 0 [0, 0]
SF-36 Role limitations, emotional
All
16, 0 [0, 33]
% SDS ≥ 80%
4, 0 [0, 0]
LV ejection fraction (%)
All
30, 28 [23, 40]
% SDS ≥ 80%
31, 28 [23, 40]
LV end-systolic volume (mL)
All
146, 136 [123, 170]
% SDS ≥ 80%
144, 136 [125, 140]
Device-based physical activity (au)
All
81, 80 [58, 115]
% SDS ≥ 80%
83, 84 [51, 119]

3 month follow up

6 month follow up

12 month follow up

321, 333 [310, 349]
321, 336 [319, 349]

324, 336 [322, 350]
333, 347 [329, 357]*

336, 340 [315, 368]*
344, 346 [328, 385]*

17, 0 [0, 25]
11, 0 [0, 25]

29, 38 [0, 50]*
39, 50 [25, 50]*

21, 25 [0, 50]*
25, 25 [0, 50]*

38, 67 [0, 67]
44, 67 [0, 67]*

41, 50 [0, 67]*
52, 67 [33, 67]*

46, 33 [33, 67]*
48, 33 [33, 67]*

30, 31 [20, 39]
39, 39 [34, 43]

40, 39 [28, 51]
45, 43 [39, 51]

35, 34 [29, 38]
36, 34 [34, 38]*

162, 125 [91, 203]
118, 102 [91, 154]

136, 132 [77, 150]
105, 115 [77, 132]

103, 98 [89, 106]*
97, 98 [91, 105]*

108, 109 [84, 140]
115, 110 [98, 145]

121, 119 [106, 140]
122, 119 [102, 136]

135, 151 [127, 160]
135, 151 [127, 163]

Values are mean, median, and [quartiles]. One patient with SDS < 80% died before the 6 month assessment. One patient with SDS < 80%
died before the 12 month assessment.
*
P value < 0.05 follow up compared with discharge; activity follow up compared with 3 month.

Figure 3 Change from discharge to 3, 6, and 12 months post-implant in 6MHW distance and echocardiographic parameters (LVEF and LVESV) for A (all
patients) and B (patients with synchronized % SDS ≥ of cardiac beats). Radar charts show changes from discharge to 12 months post-implant for 6MHW
distance, LVEF, LVESV, and SF-36 QOL parameters for C (all patients) and D (patients with synchronized % SDS ≥ of cardiac beats).

Discussion
Synchronized diaphragmatic stimulation (SDS) is a novel approach to try to improve cardiac function, symptoms, and ultimately, outcome for patients with HFrEF. This study takes
several important steps towards realizing the therapeutic po-

tential of SDS. It demonstrates the feasibility of a minimally
invasive implant procedure with a low rate of complications.
It also shows that SDS can be delivered without causing untoward symptoms from diaphragmatic pacing and that this
can be maintained for at least 1 year. However, this was an
observational study and cannot distinguish outcomes with
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an intervention from the response to it, which require randomized trials.6,7 However, investigators were blind to the
percentage of SDS successfully delivered, and therefore, the
observation that patients who received more SDS appeared
to do better provides some further encouragement.
This is the ﬁrst study of the VisONE system. Investigators
rapidly developed the technical skills to deliver diaphragmatic
leads laparoscopically. The average procedure time was
73 min. Laparoscopic surgeons had a training session with a
simulator, thus there was no evidence of a learning curve in
clinical practice for the routine laparoscopic approach. The
procedure does require an anaesthetic but could be done
as an outpatient procedure.
Phrenic nerve and diaphragmatic pacing are potential complication of CRT, which may cause hiccoughs. Consistent with
previous reports,3,8 this study shows that it is possible to
stimulate the diaphragm asymptomatically and without causing diaphragmatic fatigue. The rapid fall in lead impedance
after implantation suggests that the energy required for diaphragmatic capture may fall over the ﬁrst year; hopefully, this
will be maintained longer term.
The Epiphrenic II pilot cross-over trial (3 week treatment
periods) found that SDS, using a modiﬁed CRT device, improved dyspnoea, exercise capacity, and LVEF in patients with
chronic HFrEF.4 Observing patients for a further year, with
SDS programmed on,5 suggested that diaphragmatic
pacingdid not cause adverse symptoms and that stimulation
thresholds were stable.
The potential mechanisms of action of SDS require further
elucidation. Diaphragmatic movement during inspiration reduces intrathoracic and increases intra-abdominal pressure,
increasing systemic venous return. The fall in intrathoracic
pressure increases pulmonary venous capacitance and reduces ﬂow into the left atrium, but transmural atrial pressures gradients may be maintained or increase.9 RA and RV
volume will increase and LA and LV volume decrease during
inspiration (refer to Figure S3). Reduction in pericardial restraint may also occur.9 In a porcine model with continuous
intrathoracic pressure recording, SDS produced biphasic
changes in intrathoracic pressure and increased cardiac
output.10 Using high-frequency, jet-ventilation, Pinsky et al.
found that increased intrathoracic pressure pulses during systole improved cardiac performance11,12 due to changes in LV
afterload and impedance and in venous return. Recently, a
device for intrathoracic pressure regulation has been developed to decrease intrathoracic pressure to improve cardiac
function in emergency situations.13
The SDS therapy dose response is deﬁned by the number
of cardiac beats appropriately sensed (% SDS) so that diaphragmatic stimulation can be effectively delivered. For the
results presented herein, the 80% SDS dose threshold was
chosen, not pre-speciﬁed, after analysis of diagnostic data
stored within the IPG (refer to Figure S1) because it appeared
to identify responders. We consider it reasonable to suggest

that successful delivery of the intended intervention might
be associated with a better response, but we also admit that
this could reﬂect conﬁrmation bias in a post hoc analysis. As
SDS stimulation is imperceptible to the patient and the % SDS
determination was done ofﬂine during data analysis, both the
patient and investigators were blinded to the dose delivered.
The software in this ﬁrst-generation device was not always
successful in identifying QRS complexes due to interference
from diaphragmatic electromyographic activity especially in
the presence of low amplitude R waves, which reduced the
% SDS for some patients. Using data collected by the IPG, a
database was developed to optimize the ECG detection ﬁlter,
which will be used to enhance the next generation VisOne
system. Future research will pre-specify SDS thresholds for investigation of treatment response.
This study has several limitations. Only a few patients were
enrolled that cannot reﬂect the great diversity of HFrEF and it
had no control group. The study also provided limited insights
into the potential mechanisms by which SDS might beneﬁt
patients with HFrEF and did not evaluate RV function.
In conclusion, this study demonstrates the feasibility of delivering, asymptomatic, long-term SDS by a minimally invasive
procedure. It appears safe. These encouraging observational
data now need to be validated in randomized trials.
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Figure S1. Dose-response (% SDS) over 12 months on a per
patient basis: SDS should be delivered for each heart beat
at the appropriate time in the cardiac cycle. To achieve this
goal, the ECG (R-wave) must be detected by sensor-leads attached to the diaphragm, but this can be contaminated with
electromyographic (EMG) noise from diaphragmatic muscle
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during respiration. The ﬁrst-generation VisONE IPG did not
optimally remove diaphragmatic EMG noise, which impaired
ECG R-wave detection (sensing) for some patients, especially
those with low amplitude R-waves. The IPG maintains statistics on the sensing performance (% synchronized stimulation,
%SDS), which can be downloaded at clinic visits. The ﬁgure
shows %SDS for the patients in this study over 12 months.
By approximately 3 months, a group of patients with %SDS
≥80% (n=9) was identiﬁed, providing an opportunity to as-

sess, informally, the dose-response to SDS.
Figure S2. Examples of original device (1st generation) ﬁlter
results for sensing the ECG from the diaphragm and the 2nd
generation ﬁlter results optimized to remove EMG noise artifact.
Figure S3. Illustration of proposed acute and chronic effects
of SDS. Abbreviations: RA- right atrial, RV- right ventricular,
LA- left atrial, LV- left ventricular.
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